<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD04840000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P14324</UniProt_ID>
  <Seq_Length>419</Seq_Length>
  <Molecule_Weight>48275</Molecule_Weight>
  <KEGG_ID>hsa:2224</KEGG_ID>
  <Orthology_ID>K00787</Orthology_ID>
  <Function_Summary>Key enzyme in isoprenoid biosynthesis which catalyzes the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids, and ubiquinones. FPP also serves as substrate for protein farnesylation and geranylgeranylation. Catalyzes the sequential condensation of isopentenyl pyrophosphate with the allylic pyrophosphates, dimethylallyl pyrophosphate, and then with the resultant geranylpyrophosphate to the ultimate product farnesyl pyrophosphate.</Function_Summary>
  <Catalytic_Mechanism>Dimethylallyl diphosphate + isopentenyl diphosphate = diphosphate + geranyl diphosphate.@@Geranyl diphosphate + isopentenyl diphosphate = diphosphate + (2E,6E)-farnesyl diphosphate.</Catalytic_Mechanism>
  <Pfam_ID>PF00348:polyprenyl_synt</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>68</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>Geranyltranstransferase</Alias>
      <Alias>2.5.1.1&lt;/ecNumber</Alias>
      <Alias>Dimethylallyltranstransferase</Alias>
      <Alias>FPS</Alias>
      <Alias>Farnesyl diphosphate synthase</Alias>
      <Alias>FPP synthase</Alias>
      <Alias>(2E,6E)-farnesyl diphosphate synthase</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Catalysis of the reaction: geranyl diphosphate + isopentenyl diphosphate = 2-trans,6-trans-farnesyl diphosphate + diphosphate.</Detail>
      <Keyword>Geranyltranstransferase activity</Keyword>
      <Ontology_ID>GO:0004337</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any metal ion.</Detail>
      <Keyword>Metal ion binding</Keyword>
      <Ontology_ID>GO:0046872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the transfer of a group, e.g. a methyl group, glycosyl group, acyl group, phosphorus-containing, or other groups, from one compound (generally regarded as the donor) to another compound (generally regarded as the acceptor). Transferase is the systematic name for any enzyme of EC class 2.</Detail>
      <Keyword>Transferase activity</Keyword>
      <Ontology_ID>GO:0016740</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the reaction: dimethylallyl diphosphate + isopentenyl diphosphate = diphosphate + geranyl diphosphate.</Detail>
      <Keyword>Dimethylallyltranstransferase activity</Keyword>
      <Ontology_ID>GO:0004161</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>364</Position>
      <Original>Val</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>391</Position>
      <Original>Ile</Original>
      <Variation>Val</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>The chemical reactions and pathways resulting in the formation of sterols, steroids with one or more hydroxyl groups and a hydrocarbon side-chain in the molecule.</Detail>
      <Keyword>Sterol biosynthetic process</Keyword>
      <Ontology_ID>GO:0016126</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways resulting in the formation of lipids, compounds soluble in an organic solvent but not, or sparingly, in an aqueous solvent.</Detail>
      <Keyword>Lipid biosynthetic process</Keyword>
      <Ontology_ID>GO:0008610</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways resulting in the formation of steroids, compounds with a 1,2,cyclopentanoperhydrophenanthrene nucleus; includes de novo formation and steroid interconversion by modification.</Detail>
      <Keyword>Steroid biosynthetic process</Keyword>
      <Ontology_ID>GO:0006694</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process in which an organism has an effect on an organism of a different species.</Detail>
      <Keyword>Interspecies interaction between organisms</Keyword>
      <Ontology_ID>GO:0044419</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways resulting in the formation of any isoprenoid compound, isoprene (2-methylbuta-1,3-diene) or compounds containing or derived from linked isoprene (3-methyl-2-butenylene) residues.</Detail>
      <Keyword>Isoprenoid biosynthetic process</Keyword>
      <Ontology_ID>GO:0008299</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways resulting in the formation of cholesterol, cholest-5-en-3 beta-ol, the principal sterol of vertebrates and the precursor of many steroids, including bile acids and steroid hormones.</Detail>
      <Keyword>Cholesterol biosynthetic process</Keyword>
      <Ontology_ID>GO:0006695</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>353</Position>
      <PTM_Type>N6-acetyllysine</PTM_Type>
    </PTM>
    <PTM>
      <Position>123</Position>
      <PTM_Type>N6-acetyllysine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MPLSRWLRSVGVFLLPAPYWAPRERWLGSLRRPSLVHGYPVLAWHSARCWCQAWTEEPRALCSSLRMNGDQNSDVYAQEKQDFVQHFSQIVRVLTEDEMGHPEIGDAIARLKEVLEYNAIGGKYNRGLTVVVAFRELVEPRKQDADSLQRAWTVGWCVELLQAFFLVADDIMDSSLTRRGQICWYQKPGVGLDAINDANLLEACIYRLLKLYCREQPYYLNLIELFLQSSYQTEIGQTLDLLTAPQGNVDLVRFTEKRYKSIVKYKTAFYSFYLPIAAAMYMAGIDGEKEHANAKKILLEMGEFFQIQDDYLDLFGDPSVTGKIGTDIQDNKCSWLVVQCLQRATPEQYQILKENYGQKEAEKVARVKALYEELDLPAVFLQYEEDSYSHIMALIEQYAAPLPPAVFLGLARKIYKRRK</Protein_Seq>
    <DNA_Seq>AGGAGTACCCGCCAACAAGCGGGACCGAGCAGGAATCCGTATCTGGGAACAGGTGAGAGAGGATGTGTGCTGGGCCTTGGAGGAAGGGGGCCGAGACCGGGCCTTACTTCTGTAACGATACTGTGAGGCATCGGAAGGCCAGCCTGTTGTGTCCGTTTTGAAGGATGCCCCTGTCCCGCTGGTTGAGATCTGTGGGGGTCTTCCTGCTGCCAGCCCCCTACTGGGCACCCCGGGAGAGGTGGCTGGGTTCCCTACGGCGGCCCTCCCTGGTGCACGGGTACCCAGTCCTGGCCTGGCACAGTGCCCGCTGCTGGTGCCAAGCGTGGACAGAGGAACCTCGAGCCCTTTGCTCCTCCCTCAGAATGAACGGAGACCAGAATTCAGATGTTTATGCCCAAGAAAAGCAGGATTTCGTTCAGCACTTCTCCCAGATCGTTAGGGTGCTGACTGAGGATGAGATGGGGCACCCAGAGATAGGAGATGCTATTGCCCGGCTCAAGGAGGTCCTGGAGTACAATGCCATTGGAGGCAAGTATAACCGGGGTTTGACGGTGGTAGTAGCATTCCGGGAGCTGGTGGAGCCAAGGAAACAGGATGCTGATAGTCTCCAGCGGGCCTGGACTGTGGGCTGGTGTGTGGAACTGCTGCAAGCTTTCTTCCTGGTGGCAGATGACATCATGGATTCATCCCTTACCCGCCGGGGACAGATCTGCTGGTATCAGAAGCCGGGCGTGGGTTTGGATGCCATCAATGATGCTAACCTCCTGGAAGCATGTATCTACCGCCTGCTGAAGCTCTATTGCCGGGAGCAGCCCTATTACCTGAACCTGATCGAGCTCTTCCTGCAGAGTTCCTATCAGACTGAGATTGGGCAGACCCTGGACCTCCTCACAGCCCCCCAGGGCAATGTGGATCTTGTCAGATTCACTGAAAAGAGGTACAAATCTATTGTCAAGTACAAGACAGCTTTCTACTCCTTCTACCTTCCTATAGCTGCAGCCATGTACATGGCAGGAATTGATGGCGAGAAGGAGCACGCCAATGCCAAGAAGATCCTGCTGGAGATGGGGGAGTTCTTTCAGATTCAGGATGATTACCTTGACCTCTTTGGGGACCCCAGTGTGACCGGCAAAATTGGCACTGACATCCAGGACAACAAATGCAGCTGGCTGGTGGTTCAGTGTCTGCAACGGGCCACTCCAGAACAGTACCAGATCCTGAAGGAAAATTACGGGCAGAAGGAGGCTGAGAAAGTGGCCCGGGTGAAGGCGCTATATGAGGAGCTGGATCTGCCAGCAGTGTTCTTGCAATATGAGGAAGACAGTTACAGCCACATTATGGCTCTCATTGAACAGTACGCAGCACCCCTGCCCCCAGCCGTCTTTCTGGGGCTTGCGCGCAAAATCTACAAGCGGAGAAAGTGACCTAGAGATTGCAAGGGCGGGGAGAGGAGGCTCTCAATAAATAATCGTGTAACCTTCAAAAAAAAAAAAAAAAAAA</DNA_Seq>
  </Molecule_Seq>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleus</CellLocal>
      <Ontology_ID>GO:0005634</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytoplasm</CellLocal>
      <Ontology_ID>GO:0005737</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytosol</CellLocal>
      <Ontology_ID>GO:0005829</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>FDPS</Gene_Name>
    <Gene_Alias>FPS; KIAA1293</Gene_Alias>
    <Gene_ID>2224</Gene_ID>
    <Genbank_ACCN>NM_001135821</Genbank_ACCN>
    <Protein_ACCN>NP_001129293</Protein_ACCN>
    <HGNC_ID>3631</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/2224</Gene_URL>
    <UCSC_ID>uc001fkc.2</UCSC_ID>
    <EMBL_ID>ENSG00000160752</EMBL_ID>
  </Gene>
  <Disease_List>
    <Disease>
      <Disease_Name>Osteonecrosis of the Jaw</Disease_Name>
      <Disease_Detail>Osteonecrosis of the Jaw</Disease_Detail>
      <Disease_DB>OST115</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/osteonecrosis_of_the_jaw?search=FDPS#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Human FPPS complex with NOV_823</PDB_Title>
      <PDB_ID>3N6K</PDB_ID>
      <Resolution>2.25</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3N6K</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD04842011</ASD_Ligand>
      <PubMed_Title>Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery.</PubMed_Title>
      <Author>Jahnke, W., et al.</Author>
      <Journal>Nat.Chem.Biol.(2010)6:660-666</Journal>
      <PubMed_ID>20711197</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human FPPS COMPLEX WITH FBS_02</PDB_Title>
      <PDB_ID>3N1W</PDB_ID>
      <Resolution>2.56</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3N1W</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD04840001</ASD_Ligand>
      <PubMed_Title>Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery.</PubMed_Title>
      <Author>Jahnke, W., et al.</Author>
      <Journal>Nat.Chem.Biol.(2010)6:660-666</Journal>
      <PubMed_ID>20711197</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human FPPS complex with NOV_980 and zoledronic acid/MG2+</PDB_Title>
      <PDB_ID>3N46</PDB_ID>
      <Resolution>2.35</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3N46</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD04840008</ASD_Ligand>
      <PubMed_Title>Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery.</PubMed_Title>
      <Author>Jahnke, W., et al.</Author>
      <Journal>Nat.Chem.Biol.(2010)6:660-666</Journal>
      <PubMed_ID>20711197</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN FDPS SYNTHASE IN COMPLEX WITH MINODRONATE</PDB_Title>
      <PDB_ID>2VF6</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2VF6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Human Fdps Synthase in Complex with Novel Inhibitor</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Unliganded Human FPPS</PDB_Title>
      <PDB_ID>2F7M</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2F7M</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs.</PubMed_Title>
      <Author>Rondeau, J.M., et al.</Author>
      <Journal>Chemmedchem(2006)1:267-273</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16892359?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human farnesyl diphosphate synthase (T201A mutant) complexed with Mg and biphosphonate inhibitor</PDB_Title>
      <PDB_ID>3CP6</PDB_ID>
      <Resolution>1.95</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3CP6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Human farnesyl diphosphate synthase (T201A mutant) complexed with Mg and biphosphonate inhibitor.</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>X-ray structure of Farnesyl diphosphate synthase protein</PDB_Title>
      <PDB_ID>1ZW5</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ZW5</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs.</PubMed_Title>
      <Author>Kavanagh, K.L., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2006)103:7829-7834</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16684881?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of FPPS in complex with Zoledronate</PDB_Title>
      <PDB_ID>2F8C</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2F8C</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs.</PubMed_Title>
      <Author>Rondeau, J.M., et al.</Author>
      <Journal>Chemmedchem(2006)1:267-273</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16892359?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human fpps complex with NOV_304</PDB_Title>
      <PDB_ID>3N5H</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3N5H</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD04842004</ASD_Ligand>
      <PubMed_Title>Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery.</PubMed_Title>
      <Author>Jahnke, W., et al.</Author>
      <Journal>Nat.Chem.Biol.(2010)6:660-666</Journal>
      <PubMed_ID>20711197</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human FDPS synthase in complex with novel inhibitor</PDB_Title>
      <PDB_ID>2RAH</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2RAH</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Human FDPS synthase in complex with novel inhibitor</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Human FPPS complex with FBS_03</PDB_Title>
      <PDB_ID>3N3L</PDB_ID>
      <Resolution>2.74</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3N3L</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD04840003</ASD_Ligand>
      <PubMed_Title>Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery.</PubMed_Title>
      <Author>Jahnke, W., et al.</Author>
      <Journal>Nat.Chem.Biol.(2010)6:660-666</Journal>
      <PubMed_ID>20711197</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human FPPS in complex with ibandronate</PDB_Title>
      <PDB_ID>2F94</PDB_ID>
      <Resolution>1.94</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2F94</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs.</PubMed_Title>
      <Author>Rondeau, J.M., et al.</Author>
      <Journal>Chemmedchem(2006)1:267-273</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16892359?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human farnesyl diphosphate synthase complexed with risedronate</PDB_Title>
      <PDB_ID>1YQ7</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1YQ7</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Human farnesyl diphosphate complexed with clinical inhibitor risedronate</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Human farnesyl diphosphate synthase complexed with Mg and risedronate</PDB_Title>
      <PDB_ID>1YV5</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1YV5</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs.</PubMed_Title>
      <Author>Kavanagh, K.L., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2006)103:7829-7834</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16684881?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human fpps complex with NOV_311</PDB_Title>
      <PDB_ID>3N5J</PDB_ID>
      <Resolution>2.35</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3N5J</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD04842005</ASD_Ligand>
      <PubMed_Title>Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery.</PubMed_Title>
      <Author>Jahnke, W., et al.</Author>
      <Journal>Nat.Chem.Biol.(2010)6:660-666</Journal>
      <PubMed_ID>20711197</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human FPPS in complex with alendronate</PDB_Title>
      <PDB_ID>2F92</PDB_ID>
      <Resolution>2.15</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2F92</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs.</PubMed_Title>
      <Author>Rondeau, J.M., et al.</Author>
      <Journal>Chemmedchem(2006)1:267-273</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16892359?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human FPPS in complex with YS_04_70</PDB_Title>
      <PDB_ID>4DEM</PDB_ID>
      <Resolution>1.85</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4DEM</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Design and Synthesis of Active Site Inhibitors of the Human Farnesyl Pyrophosphate Synthase: Apoptosis and Inhibition of ERK Phosphorylation in Multiple Myeloma Cells.</PubMed_Title>
      <Author>Lin, Y.S., et al.</Author>
      <Journal>J.Med.Chem.(2012)55:3201-3215</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22390415?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human Farnesyl Diphosphate Synthase Complexed with Bisphosphonate BPH-461</PDB_Title>
      <PDB_ID>2OPM</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2OPM</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Lipophilic bisphosphonates as dual farnesyl/geranylgeranyl diphosphate synthase inhibitors: an X-ray and NMR investigation.</PubMed_Title>
      <Author>Zhang, Y., et al.</Author>
      <Journal>J.Am.Chem.Soc.(2009)131:5153-5162</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19309137?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human farnesyl pyrophosphate synthase T210S mutant bound to risedronate</PDB_Title>
      <PDB_ID>2QIS</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2QIS</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of human farnesyl pyrophosphate synthase T210S mutant bound to risedronate.</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human FPPS in complex with zoledronate and isopentenyl diphosphate</PDB_Title>
      <PDB_ID>2F8Z</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2F8Z</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs.</PubMed_Title>
      <Author>Rondeau, J.M., et al.</Author>
      <Journal>Chemmedchem(2006)1:267-273</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16892359?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human Farnesyl Diphosphate Synthase Complexed with Bisphosphonate BPH-527</PDB_Title>
      <PDB_ID>2OPN</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2OPN</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Bisphosphonates: Teaching Old Drugs with New Tricks</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Human farnesyl diphosphate synthase complexed with MG and minodronate</PDB_Title>
      <PDB_ID>3B7L</PDB_ID>
      <Resolution>1.95</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3B7L</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Human farnesyl diphosphate synthase complexed with MG and minodronate.</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human FPPS in complex with Zoledronate and Zn2+</PDB_Title>
      <PDB_ID>2F9K</PDB_ID>
      <Resolution>2.06</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2F9K</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs.</PubMed_Title>
      <Author>Rondeau, J.M., et al.</Author>
      <Journal>Chemmedchem(2006)1:267-273</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16892359?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human FDPS Synthase in Complex with a N-Methyl Pyridinum Bisphosphonate</PDB_Title>
      <PDB_ID>3RYE</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3RYE</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Human FDPS Synthase in Complex with a N-Methyl Pyridinum Bisphosphonate</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Human FPPS COMPLEX WITH FBS_01</PDB_Title>
      <PDB_ID>3N1V</PDB_ID>
      <Resolution>2.18</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3N1V</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD04840002</ASD_Ligand>
      <PubMed_Title>Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery.</PubMed_Title>
      <Author>Jahnke, W., et al.</Author>
      <Journal>Nat.Chem.Biol.(2010)6:660-666</Journal>
      <PubMed_ID>20711197</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human FPPS in complex with pamidronate</PDB_Title>
      <PDB_ID>2F89</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2F89</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs.</PubMed_Title>
      <Author>Rondeau, J.M., et al.</Author>
      <Journal>Chemmedchem(2006)1:267-273</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16892359?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human FDPS Synthase in Complex with a Rigid Analog of Risedronate</PDB_Title>
      <PDB_ID>3S4J</PDB_ID>
      <Resolution>1.95</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3S4J</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Human FDPS Synthase in Complex with a Rigid Analog of Risedronate</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Human FPPS complex with FBS_04 and zoledronic acid/MG2+</PDB_Title>
      <PDB_ID>3N45</PDB_ID>
      <Resolution>1.88</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3N45</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD04840004</ASD_Ligand>
      <PubMed_Title>Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery.</PubMed_Title>
      <Author>Jahnke, W., et al.</Author>
      <Journal>Nat.Chem.Biol.(2010)6:660-666</Journal>
      <PubMed_ID>20711197</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human FPPS COMPLEX WITH NOV_292</PDB_Title>
      <PDB_ID>3N49</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3N49</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD04840007</ASD_Ligand>
      <PubMed_Title>Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery.</PubMed_Title>
      <Author>Jahnke, W., et al.</Author>
      <Journal>Nat.Chem.Biol.(2010)6:660-666</Journal>
      <PubMed_ID>20711197</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko05164</Pathway_ID>
      <Pathway_Title>Influenza A</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko00900</Pathway_ID>
      <Pathway_Title>Terpenoid backbone biosynthesis</Pathway_Title>
      <Pathway_Class>Metabolism</Pathway_Class>
      <Pathway_Subclass>Metabolism of terpenoids and polyketides</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko00900</Pathway_ID>
      <Pathway_Title>Terpenoid backbone biosynthesis</Pathway_Title>
      <Pathway_Class>Metabolism</Pathway_Class>
      <Pathway_Subclass>Metabolism of terpenoids and polyketides</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05166</Pathway_ID>
      <Pathway_Title>HTLV-I infection</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <CATH_Class>Class 1: Mainly Alpha</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1yq7</CATH_URL>
  </Fold>
  <AllostericSite_List>
    <AllostericSite>
      <Site_Detail>site,123,Lys;site,125,Asn;site,126,Arg;site,272,Phe;site,305,Phe;site,410,Leu;site,414,Ile;site,416,Lys</Site_Detail>
      <Site_Reference>Jahnke W, et al. Nat Chem Biol. 2010,6(9):660-666</Site_Reference>
      <PDB_ID>3N1V;3N1W;3N3L;3N45;3N46;3N49;3N5H;3N5J;3N6K</PDB_ID>
      <PubMed_ID>20711197</PubMed_ID>
    </AllostericSite>
  </AllostericSite_List>
  <Enzyme_Nomenclature_List>
    <Enzyme_Nomenclature>
      <Enzyme_DB_ID>2.5.1.10</Enzyme_DB_ID>
      <Enzyme_DB_URL>http://www.chem.qmul.ac.uk/iubmb/enzyme/EC2/5/1/10.html</Enzyme_DB_URL>
    </Enzyme_Nomenclature>
  </Enzyme_Nomenclature_List>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD04840001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840002</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840003</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840004</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840005</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840006</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840007</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840008</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840009</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840010</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840011</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840012</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840013</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840014</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840015</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840016</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840017</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840018</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840019</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840020</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840021</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840022</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840023</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840024</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840025</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840026</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840027</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840028</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840029</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840030</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840031</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840032</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840033</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840034</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840035</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840036</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840037</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840038</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840039</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840040</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840041</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840042</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840043</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840045</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840046</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840047</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840048</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840049</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840050</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840051</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840052</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840053</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840054</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840055</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840056</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840057</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04840058</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04842001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04842002</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04842003</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04842004</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04842005</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04842006</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04842007</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04842008</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04842009</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04842010</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04842011</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-06-20</Create_Date>
</Organism_Record>